A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Recruiting now · Phase 2

Conditions studied: Relapsed or Refractory Multiple Myeloma

In brief

This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.

Key facts

Study ID

NCT07312188

Run by

Shandong New Time Pharmaceutical Co., LTD

People needed

90

Starts

2025-07-02

Expected to finish

2028-05-20

Last updated by the study team

2025-12-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be diagnosed with multiple myeloma according to the IMWG 2016 criteria.
• The previous treatment regimen must contain lenalidomide (lenalidomide must be used continuously for at least 2 cycles) and a proteasome inhibitor.
• Participants whose previous treatment regimen contained pomalidomide or who were intolerant to pomalidomide cannot be enrolled.
• Have an ECOG performance status score of 0 - 2.
• Meet at least one of the following measurable disease indicators:
• Serum M - protein ≥ 5 g/L.
• Urine M - protein ≥ 200 mg/24 h.
• Serum free light chain (FLC) test: Involved FLC level ≥ 100 mg/L and abnormal serum free light chain ratio (< 0.26 or > 1.65).

You may not qualify if…

• Patients with primary light - chain amyloidosis or plasma cell leukemia .
• Patients with symptoms of central nervous system involvement of multiple myeloma.
• Patients with a history of other malignancies other than multiple myeloma within 3 years before the first dose.
• Patients with active mucosal or visceral bleeding.
• Patients who have previously received BCMA - targeted therapy.

Where it is running

• Institute of Hematology & Blood Diseases Hospital — Tianjin, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.